ArticleBritish journal of cancer2005
Reduced expression of chemokine (C-C motif) ligand-2 (CCL2) in ovarian adenocarcinoma.
Article in British journal of cancer, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 31 citations in OpenAlex.
- Human umbilical cord mesenchymal stem cells promoted tumor cell growth associated with increased interleukin-18 in hepatocellular carcinoma.Molecular biology reports · 2024Article
- Identification of CXCL10-Relevant Tumor Microenvironment Characterization and Clinical Outcome in Ovarian Cancer.Frontiers in genetics · 2021Article
- CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of the Ligands of Receptors CCR1, CCR2, CCR3, and CCR4.International journal of molecular sciences · 2020Review
- Observational
- Network pharmacology-based strategy to investigate pharmacological mechanisms of Zuojinwan for treatment of gastritis.BMC complementary and alternative medicine · 2018Article
- Increased expression of C-C motif ligand 2 associates with poor prognosis in patients with gastric cancer after gastrectomy.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Transcriptional regulation of chemokine expression in ovarian cancer.Biomolecules · 2015Review
- Genetic variations in monocyte chemoattractant protein-1 and susceptibility to ovarian cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Expression of monocyte chemotactic protein-1/CCL2 in gastric cancer and its relationship with tumor hypoxia.World journal of gastroenterology · 2014Article
- Overexpressing the CCL2 chemokine in an epithelial ovarian cancer cell line results in latency of in vivo tumourigenicity.Oncogenesis · 2012Article
- Gene expression analysis of matched ovarian primary tumors and peritoneal metastasis.Journal of translational medicine · 2012Article
- Copy number variation analysis of matched ovarian primary tumors and peritoneal metastasis.PloS one · 2011Article
- Chemokine signaling in cancer: Implications on the tumor microenvironment and therapeutic targeting.Cancer therapy · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemokine (C-C motif) ligand-2 (CCL2) is a chemoattractant and activator of macrophages and is a key determinant of the macrophage infiltrate into tumours. We demonstrate here that CCL2 is expressed in normal human ovarian surface epithelium (HOSE) cells and is silenced in most ovarian cancer cell lines, and silenced or downregulated in the majority of primary ovarian adenocarcinomas. Analysis of the CCL2 locus at 17q11.2-q12 showed loss of heterozygosity (LOH) in 70% of primary tumours, and this was significantly more common in tumours of advanced stage or grade. However, we did not detect any mutations in the CCL2 coding sequence in 94 primary ovarian adenocarcinomas. These data support the hypothesis that CCL2 may play a role in the pathobiology of ovarian cancers, but additional studies will be required to evaluate this possibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.